热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 药明合联（02268）盘中涨超8%，截至发稿，股价上涨7.54%，现报62.75港元，成交额3.01亿港元。 药明合联此前发布2025年业绩盈喜预告，交银国际表示，基于公司盈利预告，略微下调2025-27年收入 和经调整净利润预测1-3%，至58.8亿/82.8亿/111.1亿元（人民币，下同）、16.0亿/24.5亿/34.2亿元，分 别对应38%/46%2025-27年CAGR，强劲增速主要得益于综合CMC订单的快速增长、尤其是临床后期/商 业化阶段订单贡献的提升。 交银国际指出，据统计，2026年前两个月全球XDC赛道共发生25项投融资事件，相比2025年同期的18 项显著增长；XDC候选药物BD交易呈现类似趋势，交易数量保持稳定、合计首付款总额大幅增长。 2024年年初以来，XDC领域投融资事件数、BD交易数和首付款总额呈逐步上升态势。投融资和BD交易 持续活跃，将进一步拉动XDC CRDMO行业下游需求改善，药明合联作为技术实力和一体化交付能力 布局的龙头企业，有望持续受益于这 ...

智通财经APP获悉，药明合联(02268)盘中涨超8%，截至发稿，涨6.6%，报62.2港元，成交额2.53亿港 元。 消息面上，药明合联此前发布2025年业绩盈喜预告，交银国际表示，基于公司盈利预告，略微下调 2025-27年收入和经调整净利润预测1-3%，至58.8亿/82.8亿/111.1亿元(人民币，下同)、16.0亿/24.5 亿/34.2亿元，分别对应38%/46%2025-27年CAGR，强劲增速主要得益于综合CMC订单的快速增长、尤 其是临床后期/商业化阶段订单贡献的提升。 交银国际指出，据统计，2026年前两个月全球XDC赛道共发生25项投融资事件，相比2025年同期的18 项显著增长；XDC候选药物BD交易呈现类似趋势，交易数量保持稳定、合计首付款总额大幅增长。 2024年年初以来，XDC领域投融资事件数、BD交易数和首付款总额呈逐步上升态势。投融资和BD交易 持续活跃，将进一步拉动XDC CRDMO行业下游需求改善，药明合联作为技术实力和一体化交付能力 布局的龙头企业，有望持续受益于这一重要趋势、并扩大市场份额。 ...

25Q4收入环比持续增长，在前三季度持续经营业务收入增速基础上仍保持了全年20%以上的增长（24Q4基数不 低），Non-IFRS归母净利率来看25Q4表现稳定，达到35.1%略低于25Q3。 #TIDES业务持续高增长，国内景气回暖有望带动利润率进一步提升 25年TIDES业务收入增速超90%，考虑到26年大单带动下Chemistry业务仍将维持快速增长、毛利率提升趋势，在海 外需求稳定恢复、国内即将迎来上游拐点背景下，26年利润端仍有超预期的潜力。 【持续推荐药明康德】稀缺的增长确定性与回调下来的好位置 公司已发布25年业绩预增公告，25年收入454.6亿元（+15.8%，其中持续经营业务收入增速21.4%）超过三季报公 司指引25年全年收入435-440亿元，持续经营业务收入增速为17-18%。 25Q4收入环比持续增长，在前三季度持续经营业务收入增速基础上仍保持了全年20%以上的增长（24Q4基数不 低），Non-IFRS归母净利率来看 【持续推荐药明康德】稀缺的增长确定性与回调下来的好位置 公司已发布25年业绩预增公告，25年收入454.6亿元（+15.8%，其中持续经营业务收入增速21.4%）超过 ...

Core Viewpoint - The company has released its 2025 performance forecast, expecting a revenue of 45.456 billion yuan, representing a year-on-year growth of 15.84%, with a significant increase in adjusted net profit [1][2] Revenue and Profit Forecast - For 2025, the company anticipates a revenue of 45.456 billion yuan, with a 21% year-on-year growth in continuing operations revenue and an adjusted net profit of 14.957 billion yuan, reflecting a 41.33% increase [1][2] - In Q4 2025, the expected revenue is 12.6 billion yuan, showing a year-on-year growth of 9.19%, with an adjusted net profit of approximately 4.417 billion yuan, up 36.33% year-on-year [1][2] Performance Analysis - The overall performance is better than the annual guidance, with the 2025 revenue exceeding the previously announced guidance of 43.5-44 billion yuan [2] - The adjusted net profit margin for Q4 2025 is projected to be around 35%, an increase from 32.1% in the previous three quarters, indicating improved profitability [2] Business Growth and Capacity Expansion - The company has a robust order backlog of 59.88 billion yuan in continuing operations, a year-on-year increase of 41.2%, with TIDES orders growing by 17.1% [2] - The company is expanding its small molecule and peptide production capacity, with expectations that by the end of 2025, the total volume of small molecule active pharmaceutical ingredient reactors will exceed 4 million liters [2] Earnings Forecast - The company is projected to achieve revenues of 45.456 billion yuan in 2025, 54.635 billion yuan in 2026, and 63.577 billion yuan in 2027, with respective year-on-year growth rates of 15.84%, 20.19%, and 16.37% [3] - The expected net profits for the same years are 19.151 billion yuan, 17.060 billion yuan, and 19.660 billion yuan, with year-on-year growth rates of 102.65%, -10.92%, and 15.24% respectively [3]

Core Insights - WuXi AppTec (603259.SH/2359.HK) presented at the 44th JPM Healthcare Conference, updating on its business progress [1] Group 1: Business Development - The company’s small molecule API synthesis capacity reached 4 million liters by the end of 2025, indicating a robust commercial supply system built over 25 years [1] - As of Q3 last year, WuXi AppTec's small molecule CDMO pipeline totaled 3,430, with 80 commercial molecules, representing 16% of the global clinical stage small molecule new drugs [1] Group 2: Financial Performance - WuXi AppTec expects a revenue of approximately 45.456 billion yuan for the full year 2025, reflecting a year-on-year growth of 15.84%, with a 21.4% increase in revenue from continuing operations [1] - The company anticipates a significant profit increase, with net profit attributable to shareholders expected to be around 19.151 billion yuan, a substantial year-on-year growth of 102.65% [1] - Adjusted non-IFRS net profit is projected at approximately 14.957 billion yuan, a year-on-year increase of 41.33%, while the net profit after deducting non-recurring items is expected to be about 13.241 billion yuan, up 32.56% year-on-year [1] - The pre-announcement data indicates that WuXi AppTec will achieve historical highs in revenue and the three profit metrics for 2025 [1]

Core Viewpoint - Morgan Stanley reports that WuXi AppTec (02359) has expanded its adjusted net profit margin to 33%, which is another positive surprise; the target price is set at HKD 142 with a "Buy" rating [1][4]. Financial Performance - WuXi AppTec recently issued a profit warning, expecting a 16% year-on-year increase in sales to RMB 45.5 billion for 2025, exceeding the bank's expectations by 2% [4]. - The adjusted net profit is projected to rise by 41% year-on-year to RMB 15 billion, which is 4% higher than the bank's forecast [4]. Drivers of Performance - The bank attributes the better-than-expected performance to continuous capacity and capability enhancements, production process optimization, and improvements in operational efficiency [4]. - The market is anticipated to respond positively to the profit warning [4].

Group 1 - The core viewpoint of the article highlights that Morgan Stanley has issued a report indicating that WuXi AppTec (02359) has achieved an adjusted net profit margin expansion to 33%, which is seen as a positive surprise [1] - WuXi AppTec has recently announced an earnings upgrade, projecting a 16% year-on-year sales increase to 45.5 billion RMB for 2025, exceeding Morgan Stanley's expectations by 2% [1] - The adjusted net profit is expected to rise by 41% year-on-year to 15 billion RMB, which is 4% higher than Morgan Stanley's forecast [1] Group 2 - The report attributes the better-than-expected performance to continuous capacity and capability enhancements, production process optimization, and improvements in operational efficiency [1] - It is anticipated that the market will respond positively to the earnings upgrade announcement [1]

Group 1 - The core point of the news is that Kanglong Chemical has seen a stock price increase of 5.23%, reaching 33.20 yuan per share, with a trading volume of 563 million yuan and a turnover rate of 1.22%, resulting in a total market capitalization of 59.036 billion yuan [1] - Kanglong Chemical, established on July 1, 2004, and listed on January 28, 2019, specializes in drug research, development, and production services [1] - The company's revenue composition includes laboratory services at 60.43%, CMC (small molecule CDMO) services at 21.58%, clinical research services at 14.58%, large molecule and cell and gene therapy services at 3.28%, and other services at 0.12% [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Fund has a significant position in Kanglong Chemical, with the Caitong CSI ESG 100 Index Enhanced A (000042) holding 20,700 shares, accounting for 2.08% of the fund's net value, making it the seventh-largest holding [2] - The Caitong CSI ESG 100 Index Enhanced A fund has a total scale of 35.6448 million yuan, with a year-to-date return of 2.76%, ranking 4423 out of 5517 in its category, and a one-year return of 22.03%, ranking 3429 out of 4203 [2] - The fund manager, Gu Hongyuan, has been in position for 4 years and 234 days, with the fund's total asset scale at 494 million yuan, achieving a best return of 63.85% and a worst return of -23.03% during his tenure [3]

Core Viewpoint - WuXi AppTec's stock prices surged, with A-shares rising nearly 8% to 106.5 yuan and H-shares increasing nearly 10% to 121.5 HKD, reaching new highs since October of the previous year, following the announcement of expected revenue and profit growth for 2025 [1] Financial Performance - The company anticipates achieving operating revenue of 45.456 billion yuan in 2025, representing a year-on-year increase of 15.84% [1] - Adjusted net profit attributable to shareholders is projected to be 14.957 billion yuan, reflecting a year-on-year growth of 41.33% [1] - Net profit attributable to shareholders is expected to reach 19.151 billion yuan, marking a significant year-on-year increase of 102.65% [1] Business Strategy - The anticipated performance improvement is primarily attributed to the company's focus on its unique "integrated, end-to-end" CRDMO business model [1] - Additional revenue is expected from the sale of stakes in joint ventures and the divestiture of certain business segments, contributing to investment gains [1]

Core Viewpoint - WuXi AppTec expects to achieve a revenue of approximately RMB 4,545,617 million in 2025, representing a year-on-year growth of about 15.84% [1] - The revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The company anticipates a net profit attributable to shareholders of approximately RMB 1,915,058 million, reflecting a year-on-year increase of about 102.65% [1] Summary by Category - **Revenue Projections** - Expected revenue for 2025 is approximately RMB 4,545,617 million, with a growth rate of 15.84% compared to the previous year [1] - Revenue from continuing operations is projected to grow by 21.40% year-on-year [1] - **Net Profit Expectations** - Anticipated net profit for shareholders is around RMB 1,915,058 million, indicating a significant increase of 102.65% year-on-year [1]